Alina C Boesteanu
Overview
Explore the profile of Alina C Boesteanu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
2363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jung I, Narayan V, McDonald S, Rech A, Bartoszek R, Hong G, et al.
Sci Transl Med
. 2022 Nov;
14(670):eabn7336.
PMID: 36350986
Chimeric antigen receptor (CAR) T cells have not induced meaningful clinical responses in solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during prolonged tumor antigen exposure...
2.
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4
Bhoj V, Li L, Parvathaneni K, Zhang Z, Kacir S, Arhontoulis D, et al.
Mol Ther Oncolytics
. 2021 Feb;
20:387-398.
PMID: 33614919
Metastatic medullary thyroid cancer (MTC) is a rare but often aggressive thyroid malignancy with a 5-year survival rate of less than 40% and few effective therapeutic options. Adoptive T cell...
3.
Fraietta J, Lacey S, Orlando E, Pruteanu-Malinici I, Gohil M, Lundh S, et al.
Nat Med
. 2021 Feb;
27(3):561.
PMID: 33547459
No abstract available.
4.
Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu A, Minutolo N, Gitto S, et al.
Mol Ther
. 2019 Dec;
28(2):548-560.
PMID: 31870622
The prognosis of patients diagnosed with advanced ovarian or endometrial cancer remains poor, and effective therapeutic strategies are limited. The Müllerian inhibiting substance type 2 receptor (MISIIR) is a transforming...
5.
Long K, Young R, Boesteanu A, Davis M, Melenhorst J, Lacey S, et al.
Front Immunol
. 2018 Dec;
9:2740.
PMID: 30559740
Chimeric antigen receptor (CAR)-engineered T cells represent a breakthrough in personalized medicine. In this strategy, a patient's own T lymphocytes are genetically reprogrammed to encode a synthetic receptor that binds...
6.
Yin Y, Boesteanu A, Binder Z, Xu C, Reid R, Rodriguez J, et al.
Mol Ther Oncolytics
. 2018 Oct;
11:20-38.
PMID: 30306125
We generated two humanized interleukin-13 receptor α2 (IL-13Rα2) chimeric antigen receptors (CARs), Hu07BBz and Hu08BBz, that recognized human IL-13Rα2, but not IL-13Rα1. Hu08BBz also recognized canine IL-13Rα2. Both of these...
7.
Hancock A, Stairiker C, Boesteanu A, Monzon-Casanova E, Lukasiak S, Mueller Y, et al.
J Virol
. 2018 Aug;
92(21).
PMID: 30111569
Influenza virus outbreaks remain a serious threat to public health. A greater understanding of how cells targeted by the virus respond to the infection can provide insight into the pathogenesis...
8.
Fraietta J, Lacey S, Orlando E, Pruteanu-Malinici I, Gohil M, Lundh S, et al.
Nat Med
. 2018 May;
24(5):563-571.
PMID: 29713085
Tolerance to self-antigens prevents the elimination of cancer by the immune system. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with...
9.
Posey Jr A, Schwab R, Boesteanu A, Steentoft C, Mandel U, Engels B, et al.
Immunity
. 2016 Jun;
44(6):1444-54.
PMID: 27332733
Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate robust responses against lineage restricted, non-essential targets in hematologic cancers. However, in solid tumors, the full potential of CAR T ...
10.
Carey A, Gracias D, Thayer J, Boesteanu A, Kumova O, Mueller Y, et al.
J Immunol
. 2016 Feb;
196(6):2602-13.
PMID: 26873987
Currently, there is little consensus regarding the most appropriate animal model to study acute infection and the virus-specific CD8(+) T cell (CTL) responses in neonates. TCRβ high-throughput sequencing in naive...